BR9814415A - "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis" - Google Patents

"método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"

Info

Publication number
BR9814415A
BR9814415A BR9814415-4A BR9814415A BR9814415A BR 9814415 A BR9814415 A BR 9814415A BR 9814415 A BR9814415 A BR 9814415A BR 9814415 A BR9814415 A BR 9814415A
Authority
BR
Brazil
Prior art keywords
aggregates
testing
associates
charged
macromolecule
Prior art date
Application number
BR9814415-4A
Other languages
English (en)
Inventor
Gregor Cevc
Original Assignee
Idea Innovat Dermale Appl Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idea Innovat Dermale Appl Gmbh filed Critical Idea Innovat Dermale Appl Gmbh
Publication of BR9814415A publication Critical patent/BR9814415A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Patente de Invenção: <B>"MéTODO PARA DESENVOLVER, TESTAR E UTILIZAR ASSOCIADOS DE MACROMOLéCULAS E AGREGADOS DE COMPLEXOS PARA CARGA úTIL AUMENTADA E VELOCIDADES DE DESASSOCIAçãO CONTROLáVEIS"<D>. A invenção descreve os princípios e os procedimentos adequados para o desenvolvimento, teste, fabricação e utilização de combinações de diversas macromoléculas anfipáticas, se necessário modificadas (tais como polipeptídios, proteínas, etc.) ou outras moléculas de cadeia (tais como adequadas, por exemplo, polinucleotídeos ou polissacarídeos parcialmente tornados hidrófobos) com agregados que compreende uma mistura de anfipatos polares e ou carregados e formam superfícies prolongadas que podem ser livremente suspensas ou sustentadas. Os métodos descritos podem ser utilizados para a otimização de agregados que, depois da associação com moléculas de cadeia que exercem alguma atividade ou uma função útil, são adequados para a aplicação in vitro ou in vivo, por exemplo, nos campos de transferência de drogas, diagnósticos ou catálise biológica. Como exemplos especiais, são descritas misturas de gotículas vesiculares que consistem em lipídios carregados (associados) com insulina, interferon, interleucina, fator de crescimento de nervo, calcitonina e uma imunoglobulina, etc.
BR9814415-4A 1998-10-23 1998-10-23 "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis" BR9814415A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/006750 WO2000024377A1 (en) 1998-10-23 1998-10-23 Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates

Publications (1)

Publication Number Publication Date
BR9814415A true BR9814415A (pt) 2000-10-10

Family

ID=8167110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814415-4A BR9814415A (pt) 1998-10-23 1998-10-23 "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"

Country Status (12)

Country Link
US (2) US20080311184A1 (pt)
EP (1) EP1039880A1 (pt)
JP (1) JP4838936B2 (pt)
KR (1) KR100464601B1 (pt)
CN (1) CN1192766C (pt)
AU (1) AU765385C (pt)
BR (1) BR9814415A (pt)
CA (1) CA2309633C (pt)
HU (1) HUP0102741A3 (pt)
MX (1) MXPA00006196A (pt)
NO (1) NO20003287L (pt)
WO (1) WO2000024377A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10114244A1 (de) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB2398495B (en) * 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
UA75030C2 (en) * 2005-11-30 2006-03-15 Viktor Oleksandrovych Bykov Method for obtaining stable aqueous solutions of drugs
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN102573889B (zh) 2010-07-14 2014-10-22 中国医学科学院药物研究所 一种胰岛素的脂质复合物及其制备方法和制剂
US8422540B1 (en) 2012-06-21 2013-04-16 CBF Networks, Inc. Intelligent backhaul radio with zero division duplexing
KR101849441B1 (ko) 2015-03-19 2018-04-16 김태구 캔 오프너
KR20160112915A (ko) 2015-10-23 2016-09-28 김태구 캔 오프너
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
WO2018187240A1 (en) * 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2019055463A1 (en) 2017-09-18 2019-03-21 Bayer Healthcare Llc METHODS OF INACTIVATING VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES
EP3833186A1 (en) * 2018-08-08 2021-06-16 3M Innovative Properties Company Therapeutic composition and related methods
KR20220118210A (ko) * 2021-02-18 2022-08-25 (주)아모레퍼시픽 트랜스퍼좀을 포함하는 난용성 효능물질 전달체
CN115350330B (zh) * 2022-09-01 2023-10-20 北京化工大学 一种负电性小分子调控的表面在蛋白差异性黏附上的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
JP2517094B2 (ja) * 1986-11-28 1996-07-24 ザ リポソーム カンパニー，インコーポレイテッド リン脂質組成物
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
EP0384040B1 (en) * 1989-02-24 1994-01-26 Agfa-Gevaert N.V. Dye-donor element for thermal dye sublimation transfer
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
JP2922017B2 (ja) * 1991-03-25 1999-07-19 第一製薬株式会社 経口用脂質膜構造体
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
CZ85994A3 (en) * 1991-10-16 1994-12-15 Richardson Vicks Inc Pharmaceutical preparation for local use and exhibiting increased penetration through skin
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
EP0648114B1 (de) * 1992-07-08 1997-09-17 DIANORM G. Maierhofer GmbH Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
JP3567990B2 (ja) * 1992-07-28 2004-09-22 ザ、プロクター、エンド、ギャンブル、カンパニー 架橋陽イオン重合体とアルコキシ化エーテルとを含有する局所用途用医薬組成物
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6027726A (en) * 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
DE69532622T2 (de) * 1994-12-07 2005-02-03 Tokyo Cosmos Electric Co. Ltd., , Hachioji Flächenheizelement zur Verwendung bei Spiegeln
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
JP2002533379A (ja) * 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
JP2002063747A (ja) * 2000-08-18 2002-02-28 Sony Corp 記録媒体および記録媒体原盤ならびに記録媒体の製造方法
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
KR20010033518A (ko) 2001-04-25
CA2309633C (en) 2010-12-14
CN1192766C (zh) 2005-03-16
JP2002528406A (ja) 2002-09-03
KR100464601B1 (ko) 2004-12-31
EP1039880A1 (en) 2000-10-04
HK1032745A1 (en) 2001-08-03
JP4838936B2 (ja) 2011-12-14
AU765385B2 (en) 2003-09-18
US20080311184A1 (en) 2008-12-18
CN1283107A (zh) 2001-02-07
MXPA00006196A (es) 2003-07-21
US20080279815A1 (en) 2008-11-13
AU1435099A (en) 2000-05-15
WO2000024377A1 (en) 2000-05-04
NO20003287L (no) 2000-08-23
HUP0102741A2 (hu) 2002-03-28
HUP0102741A3 (en) 2002-12-28
AU765385C (en) 2004-05-20
CA2309633A1 (en) 2000-05-04
NO20003287D0 (no) 2000-06-22

Similar Documents

Publication Publication Date Title
BR9814415A (pt) &#34;método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis&#34;
Klajnert et al. Fluorescence studies on PAMAM dendrimers interactions with bovine serum albumin
NO955351L (no) Proteininnkapslede, uopplöselige gassmikrosfærer, deres fremstilling og anvendelse som ultralydkontrastmiddel
Wang et al. Effects of oxidative damage of membrane protein thiol groups on erythrocyte membrane viscoelasticities
TR200003461T2 (tr) Adenosin A3 Alıcı Modülatörleri
ATE298253T1 (de) In vivo gentransfermethoden zur wundheilung
NO864203D0 (no) Biologiske makromolekyler.
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
Brown et al. Modulation of in vitro erythropoiesis: enhancement of erythroid colony growth by cyclic nucleotides
WO2000015790A3 (en) Leptin induced genes
Lambrechts et al. Fluorescent oxygen sensitive microbead incorporation for measuring oxygen tension in cell aggregates
PT92403A (pt) Processo para a preparacao de glicoesfingolipidos com grupos susceptiveis de aclopamento na fraccao esfingoide e de composicoes farmaceuticas que os contem
Bostock et al. Affibody-mediated controlled release of fibroblast growth factor 2
Reddi et al. The Escherichia coli chaperonin 60 (groEL) is a potent stimulator of osteoclast formation
Thomas Jr Raman spectroscopy and virus research
DE4221836A1 (de) Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator
Durand et al. In vivo hypobaric hypoxia performed during the remodeling process accelerates bone healing in mice
Mier et al. Cytocompatibility of molecularly imprinted polymers for deodorants: Evaluation on human keratinocytes and axillary-hosted bacteria
KR970706838A (ko) 조혈 단백질을 사용한 적혈구생성을 자극하는 방법(methods for stimulating erythropoiesis using hematopoietic proteins)
Erikci et al. Small physical cross-linker facilitates hyaluronan hydrogels
ES2023631A4 (es) Ensayo de fagocitosis.
DE69927669D1 (de) Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
JPS59132361A (ja) 感染に対する抵抗力の測定方法及び食細胞用組成物
Andalibi et al. Drug discovery efforts at George Mason University
Weisenberg et al. Microtubule gelation‐contraction in vitro and its relationship to component a of slow axonal transport

Legal Events

Date Code Title Description
TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE: NAO ATENDE AO REQUISITO DE NOVIDADE ( ART. 8O COMBINADO COM O ART. 11 DA LPI 9279/96); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]